instruction
stringlengths 39
316
| response
stringlengths 121
336
| text
stringlengths 194
685
|
|---|---|---|
Could you provide the median Progression-Free Survival rate for patients treated with Observation regimen? | Patients treated with the Observation have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (18, 22). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Observation regimen?
### Response: Patients treated with the Observation have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (18, 22). |
What is the median rate of Progression-Free Survival in patients who have been treated with Observation regimen? | Patients treated with the Observation have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (18, 22). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Observation regimen?
### Response: Patients treated with the Observation have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (18, 22). |
Can you inform me about the median PFS rate in patients that were treated with Observation regimen? | Patients treated with the Observation have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (18, 22). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Observation regimen?
### Response: Patients treated with the Observation have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (18, 22). |
What is the median PFS rate for patients that have undergone Observation regimen? | Patients treated with the Observation have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (18, 22). | ### Instruction: What is the median PFS rate for patients that have undergone Observation regimen?
### Response: Patients treated with the Observation have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (18, 22). |
Could you tell me the median Progression-Free Survival rate for patients who received Observation regimen? | Patients treated with the Observation have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (18, 22). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Observation regimen?
### Response: Patients treated with the Observation have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (18, 22). |
What’s the median rate of PFS in patients treated with Observation regimen? | Patients treated with the Observation have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (18, 22). | ### Instruction: What’s the median rate of PFS in patients treated with Observation regimen?
### Response: Patients treated with the Observation have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (18, 22). |
Can you share the median Progression-Free Survival rate in patients who have received Observation regimen? | Patients treated with the Observation have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (18, 22). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Observation regimen?
### Response: Patients treated with the Observation have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (18, 22). |
Can you tell me the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD)? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: Can you tell me the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD)?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
What’s the median PFS associated with Cyclophosphamide+Bortezomib+Dexamethasone (CVD)? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: What’s the median PFS associated with Cyclophosphamide+Bortezomib+Dexamethasone (CVD)?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
Could you provide the median PFS of Cyclophosphamide+Bortezomib+Dexamethasone (CVD)? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: Could you provide the median PFS of Cyclophosphamide+Bortezomib+Dexamethasone (CVD)?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
I’d like to know the median PFS of Cyclophosphamide+Bortezomib+Dexamethasone (CVD). | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: I’d like to know the median PFS of Cyclophosphamide+Bortezomib+Dexamethasone (CVD).
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
Do you have information on the median PFS of Cyclophosphamide+Bortezomib+Dexamethasone (CVD)? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: Do you have information on the median PFS of Cyclophosphamide+Bortezomib+Dexamethasone (CVD)?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
What is the median progression-free survival (PFS) for Cyclophosphamide+Bortezomib+Dexamethasone (CVD)? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: What is the median progression-free survival (PFS) for Cyclophosphamide+Bortezomib+Dexamethasone (CVD)?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
Can you inform me about the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD)? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: Can you inform me about the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD)?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
I’m interested in the median PFS of Cyclophosphamide+Bortezomib+Dexamethasone (CVD). | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: I’m interested in the median PFS of Cyclophosphamide+Bortezomib+Dexamethasone (CVD).
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
Could you tell me the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD)? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: Could you tell me the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD)?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
What is the median PFS rate for Cyclophosphamide+Bortezomib+Dexamethasone (CVD)? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: What is the median PFS rate for Cyclophosphamide+Bortezomib+Dexamethasone (CVD)?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
What is the median PFS rate in patients who have undergone Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: What is the median PFS rate in patients who have undergone Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
What’s the median PFS rate for patients receiving Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: What’s the median PFS rate for patients receiving Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
Could you provide the median Progression-Free Survival rate for patients treated with Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
What is the median rate of Progression-Free Survival in patients who have been treated with Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
Can you inform me about the median PFS rate in patients that were treated with Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
What is the median PFS rate for patients that have undergone Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: What is the median PFS rate for patients that have undergone Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
Could you tell me the median Progression-Free Survival rate for patients who received Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
What’s the median rate of PFS in patients treated with Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: What’s the median rate of PFS in patients treated with Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
Can you share the median Progression-Free Survival rate in patients who have received Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen? | Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Cyclophosphamide+Bortezomib+Dexamethasone (CVD) regimen?
### Response: Patients treated with the Cyclophosphamide+Bortezomib+Dexamethasone (CVD) have a median Progression-Free Survival (PFS) rate of 30 months, with a 95% CI of (25, 36). |
Can you tell me the median PFS for No CVD? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: Can you tell me the median PFS for No CVD?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
What’s the median PFS associated with No CVD? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: What’s the median PFS associated with No CVD?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
Could you provide the median PFS of No CVD? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: Could you provide the median PFS of No CVD?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
I’d like to know the median PFS of No CVD. | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: I’d like to know the median PFS of No CVD.
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
Do you have information on the median PFS of No CVD? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: Do you have information on the median PFS of No CVD?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
What is the median progression-free survival (PFS) for No CVD? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: What is the median progression-free survival (PFS) for No CVD?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
Can you inform me about the median PFS for No CVD? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: Can you inform me about the median PFS for No CVD?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
I’m interested in the median PFS of No CVD. | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: I’m interested in the median PFS of No CVD.
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
Could you tell me the median PFS for No CVD? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: Could you tell me the median PFS for No CVD?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
What is the median PFS rate for No CVD? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: What is the median PFS rate for No CVD?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
What is the median Progression-Free Survival (PFS) rate in patients treated with No CVD regimen? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with No CVD regimen?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
What is the median PFS rate in patients who have undergone No CVD regimen? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: What is the median PFS rate in patients who have undergone No CVD regimen?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with No CVD regimen? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with No CVD regimen?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
What’s the median PFS rate for patients receiving No CVD regimen? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: What’s the median PFS rate for patients receiving No CVD regimen?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
Could you provide the median Progression-Free Survival rate for patients treated with No CVD regimen? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with No CVD regimen?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
What is the median rate of Progression-Free Survival in patients who have been treated with No CVD regimen? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with No CVD regimen?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
Can you inform me about the median PFS rate in patients that were treated with No CVD regimen? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with No CVD regimen?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
What is the median PFS rate for patients that have undergone No CVD regimen? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: What is the median PFS rate for patients that have undergone No CVD regimen?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
Could you tell me the median Progression-Free Survival rate for patients who received No CVD regimen? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received No CVD regimen?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
What’s the median rate of PFS in patients treated with No CVD regimen? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: What’s the median rate of PFS in patients treated with No CVD regimen?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
Can you share the median Progression-Free Survival rate in patients who have received No CVD regimen? | Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received No CVD regimen?
### Response: Patients treated with the No CVD have a median Progression-Free Survival (PFS) rate of 20 months, with a 95% CI of (15, 28). |
Can you tell me the median PFS for Melflufen+Dexamethasone? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: Can you tell me the median PFS for Melflufen+Dexamethasone?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
What’s the median PFS associated with Melflufen+Dexamethasone? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: What’s the median PFS associated with Melflufen+Dexamethasone?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
Could you provide the median PFS of Melflufen+Dexamethasone? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: Could you provide the median PFS of Melflufen+Dexamethasone?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
I’d like to know the median PFS of Melflufen+Dexamethasone. | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: I’d like to know the median PFS of Melflufen+Dexamethasone.
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
Do you have information on the median PFS of Melflufen+Dexamethasone? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: Do you have information on the median PFS of Melflufen+Dexamethasone?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
What is the median progression-free survival (PFS) for Melflufen+Dexamethasone? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: What is the median progression-free survival (PFS) for Melflufen+Dexamethasone?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
Can you inform me about the median PFS for Melflufen+Dexamethasone? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: Can you inform me about the median PFS for Melflufen+Dexamethasone?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
I’m interested in the median PFS of Melflufen+Dexamethasone. | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: I’m interested in the median PFS of Melflufen+Dexamethasone.
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
Could you tell me the median PFS for Melflufen+Dexamethasone? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: Could you tell me the median PFS for Melflufen+Dexamethasone?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
What is the median PFS rate for Melflufen+Dexamethasone? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: What is the median PFS rate for Melflufen+Dexamethasone?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
What is the median PFS rate in patients who have undergone Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: What is the median PFS rate in patients who have undergone Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
What’s the median PFS rate for patients receiving Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: What’s the median PFS rate for patients receiving Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
Could you provide the median Progression-Free Survival rate for patients treated with Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
What is the median rate of Progression-Free Survival in patients who have been treated with Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
Can you inform me about the median PFS rate in patients that were treated with Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
What is the median PFS rate for patients that have undergone Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: What is the median PFS rate for patients that have undergone Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
Could you tell me the median Progression-Free Survival rate for patients who received Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
What’s the median rate of PFS in patients treated with Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: What’s the median rate of PFS in patients treated with Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
Can you share the median Progression-Free Survival rate in patients who have received Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 6.8 months, with a 95% CI of (5, 8.5). |
Can you tell me the median PFS for Pomalidomide+Dexamethasone? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: Can you tell me the median PFS for Pomalidomide+Dexamethasone?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
What’s the median PFS associated with Pomalidomide+Dexamethasone? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: What’s the median PFS associated with Pomalidomide+Dexamethasone?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
Could you provide the median PFS of Pomalidomide+Dexamethasone? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: Could you provide the median PFS of Pomalidomide+Dexamethasone?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
I’d like to know the median PFS of Pomalidomide+Dexamethasone. | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: I’d like to know the median PFS of Pomalidomide+Dexamethasone.
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
Do you have information on the median PFS of Pomalidomide+Dexamethasone? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: Do you have information on the median PFS of Pomalidomide+Dexamethasone?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
What is the median progression-free survival (PFS) for Pomalidomide+Dexamethasone? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: What is the median progression-free survival (PFS) for Pomalidomide+Dexamethasone?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
Can you inform me about the median PFS for Pomalidomide+Dexamethasone? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: Can you inform me about the median PFS for Pomalidomide+Dexamethasone?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
I’m interested in the median PFS of Pomalidomide+Dexamethasone. | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: I’m interested in the median PFS of Pomalidomide+Dexamethasone.
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
Could you tell me the median PFS for Pomalidomide+Dexamethasone? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: Could you tell me the median PFS for Pomalidomide+Dexamethasone?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
What is the median PFS rate for Pomalidomide+Dexamethasone? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: What is the median PFS rate for Pomalidomide+Dexamethasone?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Pomalidomide+Dexamethasone regimen? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Pomalidomide+Dexamethasone regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
What is the median PFS rate in patients who have undergone Pomalidomide+Dexamethasone regimen? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: What is the median PFS rate in patients who have undergone Pomalidomide+Dexamethasone regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Pomalidomide+Dexamethasone regimen? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Pomalidomide+Dexamethasone regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
What’s the median PFS rate for patients receiving Pomalidomide+Dexamethasone regimen? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: What’s the median PFS rate for patients receiving Pomalidomide+Dexamethasone regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
Could you provide the median Progression-Free Survival rate for patients treated with Pomalidomide+Dexamethasone regimen? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Pomalidomide+Dexamethasone regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
What is the median rate of Progression-Free Survival in patients who have been treated with Pomalidomide+Dexamethasone regimen? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Pomalidomide+Dexamethasone regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
Can you inform me about the median PFS rate in patients that were treated with Pomalidomide+Dexamethasone regimen? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Pomalidomide+Dexamethasone regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
What is the median PFS rate for patients that have undergone Pomalidomide+Dexamethasone regimen? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: What is the median PFS rate for patients that have undergone Pomalidomide+Dexamethasone regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
Could you tell me the median Progression-Free Survival rate for patients who received Pomalidomide+Dexamethasone regimen? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Pomalidomide+Dexamethasone regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
What’s the median rate of PFS in patients treated with Pomalidomide+Dexamethasone regimen? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: What’s the median rate of PFS in patients treated with Pomalidomide+Dexamethasone regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
Can you share the median Progression-Free Survival rate in patients who have received Pomalidomide+Dexamethasone regimen? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Pomalidomide+Dexamethasone regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (4.2, 5.7). |
Can you tell me the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). | ### Instruction: Can you tell me the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). |
What’s the median PFS associated with Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). | ### Instruction: What’s the median PFS associated with Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). |
Could you provide the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). | ### Instruction: Could you provide the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). |
I’d like to know the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd). | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). | ### Instruction: I’d like to know the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd).
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). |
Do you have information on the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). | ### Instruction: Do you have information on the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). |
What is the median progression-free survival (PFS) for Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). | ### Instruction: What is the median progression-free survival (PFS) for Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). |
Can you inform me about the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). | ### Instruction: Can you inform me about the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). |
I’m interested in the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd). | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). | ### Instruction: I’m interested in the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd).
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). |
Could you tell me the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). | ### Instruction: Could you tell me the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (4.6, 15.4). |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.